Cipla Ltd Share Price
As on 18 April 2025 at 15:49 IST
Q3 Results:
Cipla Ltd Q3 Results: Total Income in Q3 FY25 rose 7.46% to ₹7,294.58 crore, from ₹6,788.44 crore in the same period last year. Net profit increased 47.38% to ₹1,574.59 crore on a yearly basis, compared to ₹1,068.41 crore in Q3 FY24.
About Cipla Ltd
Cipla Ltd is an Indian multinational pharmaceutical company. Founded in 1935 by Khwaja Abdul Hamied as the Chemical, Industrial & Pharmaceutical Laboratories. The company’s headquarters are located in Mumbai, Maharashtra, India. It focuses on developing medications to treat diseases and various other medical conditions. Cipla Ltd operates in the pharmaceutical sector, providing a wide range of drugs, vaccines, and diagnostics. They even make contact lenses, animal health products and dietary supplements. The company is known for its innovation in developing affordable medications, which make it a significant player in the pharmaceutical industry. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
1.51%
Over 6 Months
-2.79%
Over 1 Year
12.46%
Over 3 Years
47.41%
Cipla Ltd Summary
Close
₹1,515.20
Open
₹1,498
High
₹1,522
Low
₹1,486
Volume
12,11,601
Net Turnover (in Cr)
₹183.19
52Wk High
₹1,702.05
52Wk Low
₹1,317.25
52Wk High / Low
1,317.25
1,702.05
Cipla Ltd Fundamentals
Key Financial Data
Market Cap (in Cr)
₹1,22,370.15
EPS (TTM)
57.63
Book Value (BV)
360.74
Div. Yield
0.86
%
P/E (TTM)
25.98
Price/Book Value
4.20
Delivery %
53.28
%
Face Value
2
Key Ratios
PE Ratio
29.60
PB Ratio
4.31
EV to Sales
7.26
PEG Ratio
0.48
ROA
14.47
ROE
15.50
Debt-Equity
-
Net Profit Margin
24.60
Operating Profit Margin
35.71
Cipla Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Total Revenue | 26,520.66 | 23,228.57 | 22,044.25 | 19,425.58 | 17,476.19 |
| Total Expenses | 20,623.94 | 19,007.80 | 18,368.86 | 16,135.52 | 15,298.01 |
| Profit Before Tax | 5,701.90 | 4,038.35 | 3,493.27 | 3,290.06 | 2,178.18 |
| Profit After Tax | 4,155.31 | 2,835.49 | 2,559.47 | 2,401.30 | 1,546.98 |
| Operating Profit After Depreciation | 5,986.60 | 4,330.31 | 3,781.74 | 3,450.76 | 2,375.54 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Fixed Assets | 9,782.01 | 9,504.78 | 10,005.19 | 9,791.82 | 9,962.12 |
| Total Non Current Assets | 13,325.37 | 12,658.22 | 12,390.29 | 11,942.38 | 11,956.38 |
| Total Current Assets | 19,392.45 | 16,805.06 | 14,710.83 | 13,209.51 | 11,706.18 |
| Total Assets | 32,717.82 | 29,463.28 | 27,101.12 | 25,151.89 | 23,662.56 |
| Total Shareholder's Fund | 26,706.43 | 23,407.78 | 20,841.69 | 18,326.53 | 15,763 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 4,133.91 | 3,237.65 | 3,325.90 | 3,755.20 | 3,068.45 |
| Net Cash Used In Investing Activities | -2,982.47 | -2,376.14 | -1,858.43 | -2,374.39 | 114.39 |
| Net Cash Used In Financing Activities | -1,200.43 | -958.29 | -1,599.79 | -1,239.51 | -2,948.82 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Total Revenue | 17,645 | 14,802.13 | 16,047.52 | 11,532.99 | 13,552 |
| Total Expenses | 12,698.03 | 11,610.63 | 12,243.14 | 8,748.99 | 10,587.69 |
| Profit Before Tax | 4,946.97 | 3,005.60 | 3,804.38 | 2,784 | 2,964.31 |
| Profit After Tax | 3,714.19 | 2,144.06 | 2,882.58 | 2,044.65 | 2,318.17 |
| Operating Profit After Depreciation | 4,967.22 | 3,213.77 | 3,831.31 | 2,829.07 | 3,000.36 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Fixed Assets | 3,692.51 | 3,810 | 3,927.99 | 4,022.73 | 4,088.54 |
| Total Non Current Assets | 16,195.39 | 14,225.34 | 14,114.01 | 12,771.56 | 11,378.60 |
| Total Current Assets | 14,857.84 | 13,371.13 | 11,335.04 | 10,192.18 | 9,027.06 |
| Total Assets | 31,053.23 | 27,596.47 | 25,449.05 | 22,963.74 | 20,405.66 |
| Total Shareholder's Fund | 27,973.92 | 24,638.09 | 22,513.55 | 19,927.56 | 17,402.96 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 3,726.77 | 3,035.05 | 2,773.43 | 3,460.31 | 2,018.14 |
| Net Cash Used In Investing Activities | -2,882.90 | -2,758.09 | -2,464.14 | -3,361.33 | -1,127.18 |
| Net Cash Used In Financing Activities | -708.83 | -424.77 | -426.72 | -65.80 | -693.89 |
| Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
|---|---|---|---|---|---|
| Total Revenue | 7,072.97 | 7,051.02 | 6,693.94 | 6,163.24 | 6,603.81 |
| Total Expenses | 5,084.05 | 5,165.43 | 4,978.14 | 4,847.38 | 4,856.28 |
| Profit Before Tax | 1,916.09 | 1,789.06 | 1,611.36 | 1,259.26 | 1,473.81 |
| Profit After Tax | 1,583.72 | 1,306.02 | 1,176.29 | 934.40 | 1,068.51 |
| Operating Profit after Depreciation | 2,210.53 | 2,076.20 | 1,875.99 | 1,565.19 | 1,932.16 |
| Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
|---|---|---|---|---|---|
| Total Revenue | 4,970.88 | 4,775.03 | 4,501.05 | 4,036.66 | 4,381.33 |
| Total Expenses | 3,309.05 | 3,336.99 | 3,141.19 | 3,208.77 | 3,025.47 |
| Profit Before Tax | 1,704.35 | 1,578.47 | 1,430.45 | 1,280.61 | 1,477.14 |
| Profit After Tax | 1,438.15 | 1,178.16 | 1,055.94 | 1,038.40 | 1,114.14 |
| Operating Profit after Depreciation | 1,850.52 | 1,727.18 | 1,573.38 | 1,422.87 | 1,621.22 |
Cipla Ltd Technicals
Support and Resistance
S3
S2
S1
Pivot
R1
R2
R3
S1
1,474.20
S2
1,452
S3
1,439.60
Pivot
1,486.60
R1
1,508.80
R2
1,521.20
R3
1,543.40
Moving Average
20 SMA
1,472.72
50 SMA
1,461.11
100 SMA
1,467.72
200 SMA
1,517.45
Cipla Ltd Corporate Actions
Cipla Ltd
₹13.0/Share
Announcement Date
02 Aug 2024
Record Date
02 Aug 2024
Div Yield
650%
Cipla Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,751.05 | ₹4,20,135.55 |
| Divis Laboratories Ltd | ₹5,638.35 | ₹1,49,680.48 |
| Torrent Pharmaceuticals Ltd | ₹3,254.85 | ₹1,10,153.97 |
| Mankind Pharma Ltd | ₹2,582.65 | ₹1,06,554.59 |
| Dr Reddys Laboratories Ltd | ₹1,163.70 | ₹97,105.57 |
Cipla Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| HDFC Flexi Cap Fund | 3.98% |
| SBI Nifty 50 ETF | 0.76% |
| Parag Parikh Flexi Cap Fund | 1.23% |
| HDFC Tax Saver Fund | 5.01% |
| HDFC Focused 30 Fund | 3.77% |
Cipla Ltd News
Cipla allots 23,282 equity shares under ESOS
17 Apr 2025, 04:12 pm
Cipla jumps on receiving approval from USFDA for protein-bound Paclitaxel
Cipla rallied 3.80% to Rs 1,470.15 after the firm received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Paclitaxel, a generic version of Bristol Myers Squibb's Abraxane.
11 Apr 2025, 10:12 am
Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension
11 Apr 2025, 09:27 am
Cipla to table results
On 13 May 2025
08 Apr 2025, 09:40 am
USFDA classifies cGMP inspection of Cipla's Virgonagar facility as VAI
08 Feb 2025, 11:16 am
Cipla Ltd Stock Analysis
- Annual revenue for Cipla Ltd increased by 19.21% to ₹17,645 crore in FY 2024 from ₹14,802.13 crore in FY 2023.
- Annual Net Profit for Cipla Ltd increased by 73.23% to ₹3,714.19 crore in FY 2024 from ₹2,144.06 crore in FY 2023.
- Promoter Shareholding in Cipla Ltd decreased by 5.58% in the most recent quarter, from 30.86% in September 2024 to 29.13% in December 2024.
- Cipla Ltd delivered a 1-year return of 12.46% compared to the Nifty 50, which provided a return of 8.44% as of the last trading session.
- Cipla Ltd share price moved up by 1.26% from its previous close of INR ₹1,496.40. The latest Cipla Ltd share price is INR ₹1,515.20.
- Cipla Ltd share price today has been at a low of 1,486 and a high of 1,522. Over the past 52 weeks, the Cipla Ltd share price has seen a low of 1,317.25 and a high of 1,702.05.
About Cipla Ltd
Cipla Ltd is an Indian multinational pharmaceutical company. It focuses on developing medications to treat diseases and various other medical conditions. The company operates in the pharmaceutical sector, providing a wide range of drugs, vaccines, and diagnostics. They even make contact lenses, animal health products, dietary supplements, and protein supplements.
Founded in 1935 by Khwaja Abdul Hamied as the Chemical, Industrial & Pharmaceutical Laboratories. The company’s headquarters are located in Mumbai, Maharashtra, India. The promoters of Cipla include the Hamied family, with Yusuf Hamied serving as the Chairperson and Umang Vohra as the CEO.
Cipla’s main products include medications for diseases, HIV/AIDS, oncology, and other therapeutic areas. The company is known for its innovation in developing affordable medications. For instance, they make antiretroviral drugs during the AIDS epidemic to make them more accessible. Even though Cipla is a significant player in the pharmaceutical industry. It is not the largest in terms of market share or market capitalization in India. However, it is the third-largest drug producer in India.
The promoter shareholding in Cipla is a crucial aspect of its corporate structure. The Hamied family holds a substantial stake in the company. Here is a list of their top promoters -
Cipla’s management team is led by Chairperson Yusuf Hamied and CEO Umang Vohra. They have been instrumental in steering the company towards growth and innovation. The company’s commitment to providing affordable healthcare solutions has made it a trusted name in the industry.
Cipla’s vision is to be a leading global pharmaceutical company through its innovation and technology. They aim to provide high-quality, affordable healthcare solutions. The company aims to address the needs of patients around the world. In addition, to developing and delivering a wide range of pharmaceutical products. They envision a world where everyone can get essential medications, regardless of their situation. This vision drives the company’s efforts to expand its global footprint and enhance its product portfolio.
The vision statement emphasizes Cipla’s dedication to innovation. The company invests heavily in research and development to create better medications. It invests heavily towards cutting-edge technology and scientific advancements. They strive to stay at the forefront of the pharmaceutical industry. This focus on innovation ensures that the company can give effective treatments for various ailments.
Cipla’s mission is to provide access to high-quality and affordable medicines. This is to ensure that no patient is denied treatment due to financial constraints. The company’s mission statement underscores its commitment to social responsibility. Along with the role it can play in improving public health.
Cipla aims to make a difference in the lives of patients by offering a diverse range of pharmaceutical products. Their objective is to make medicines that meet the highest standards of quality and efficacy. One of the key aspects of Cipla’s mission is its focus on affordability. The company is known for its efforts to make essential medications accessible to people in developing countries. Cipla’s pioneering work in producing affordable drugs for HIV/AIDS patients is a testament to its mission-driven approach. Moreover, by reducing the cost of life-saving medications, Cipla has played a major role in combating global health crises.
Cipla’s vision and mission are also closely aligned with its commitment to sustainability. The company recognizes the importance of environmental stewardship. Hence, it strives to minimize its ecological footprint. Cipla implements sustainable practices across its operations, from manufacturing to distribution. This includes reducing waste, conserving energy, and promoting the use of renewable resources. Plus, by adding sustainability into its business model, it aims to create a healthier planet for future generations.
At the heart of Cipla’s vision and mission is a patient-centric approach. The company prioritizes the needs and well-being of patients in all its endeavors. Cipla engages with healthcare professionals and patients to understand their needs and challenges. This approach enables the company to develop solutions that tackle certain medical conditions.
Cipla’s patient-centric philosophy extends beyond the development of medications. The company also focuses on raising awareness about various health issues. It even provides education and support to patients and caregivers.They also empower patients with knowledge and resources that enable better care. This is how Cipla aims to enhance the overall healthcare experience and improve health outcomes.
Cipla’s vision and mission reflect its unwavering commitment to improving global healthcare. The company’s focus on affordability and patient-centricity drives its efforts to make a meaningful impact on society. With these core values, Cipla continues its legacy of excellence and compassion in the industry.
Founded in 1935 by Khwaja Abdul Hamied as the Chemical, Industrial & Pharmaceutical Laboratories. The company’s headquarters are located in Mumbai, Maharashtra, India. The promoters of Cipla include the Hamied family, with Yusuf Hamied serving as the Chairperson and Umang Vohra as the CEO.
Cipla’s main products include medications for diseases, HIV/AIDS, oncology, and other therapeutic areas. The company is known for its innovation in developing affordable medications. For instance, they make antiretroviral drugs during the AIDS epidemic to make them more accessible. Even though Cipla is a significant player in the pharmaceutical industry. It is not the largest in terms of market share or market capitalization in India. However, it is the third-largest drug producer in India.
The promoter shareholding in Cipla is a crucial aspect of its corporate structure. The Hamied family holds a substantial stake in the company. Here is a list of their top promoters -
- Y K Hamied
- M K Hamied
- Umang Vohra
- Samina Hamied
- S Radhakrishnan
Cipla’s management team is led by Chairperson Yusuf Hamied and CEO Umang Vohra. They have been instrumental in steering the company towards growth and innovation. The company’s commitment to providing affordable healthcare solutions has made it a trusted name in the industry.
Vision and Mission
Cipla Ltd is a leading pharmaceutical company. Hence, it has a clear and compelling vision and mission that guide its operations and strategic decisions. These statements reflect the company’s commitment to better healthcare and making a positive impact on society.Cipla’s vision is to be a leading global pharmaceutical company through its innovation and technology. They aim to provide high-quality, affordable healthcare solutions. The company aims to address the needs of patients around the world. In addition, to developing and delivering a wide range of pharmaceutical products. They envision a world where everyone can get essential medications, regardless of their situation. This vision drives the company’s efforts to expand its global footprint and enhance its product portfolio.
The vision statement emphasizes Cipla’s dedication to innovation. The company invests heavily in research and development to create better medications. It invests heavily towards cutting-edge technology and scientific advancements. They strive to stay at the forefront of the pharmaceutical industry. This focus on innovation ensures that the company can give effective treatments for various ailments.
Cipla’s mission is to provide access to high-quality and affordable medicines. This is to ensure that no patient is denied treatment due to financial constraints. The company’s mission statement underscores its commitment to social responsibility. Along with the role it can play in improving public health.
Cipla aims to make a difference in the lives of patients by offering a diverse range of pharmaceutical products. Their objective is to make medicines that meet the highest standards of quality and efficacy. One of the key aspects of Cipla’s mission is its focus on affordability. The company is known for its efforts to make essential medications accessible to people in developing countries. Cipla’s pioneering work in producing affordable drugs for HIV/AIDS patients is a testament to its mission-driven approach. Moreover, by reducing the cost of life-saving medications, Cipla has played a major role in combating global health crises.
Cipla’s vision and mission are also closely aligned with its commitment to sustainability. The company recognizes the importance of environmental stewardship. Hence, it strives to minimize its ecological footprint. Cipla implements sustainable practices across its operations, from manufacturing to distribution. This includes reducing waste, conserving energy, and promoting the use of renewable resources. Plus, by adding sustainability into its business model, it aims to create a healthier planet for future generations.
At the heart of Cipla’s vision and mission is a patient-centric approach. The company prioritizes the needs and well-being of patients in all its endeavors. Cipla engages with healthcare professionals and patients to understand their needs and challenges. This approach enables the company to develop solutions that tackle certain medical conditions.
Cipla’s patient-centric philosophy extends beyond the development of medications. The company also focuses on raising awareness about various health issues. It even provides education and support to patients and caregivers.They also empower patients with knowledge and resources that enable better care. This is how Cipla aims to enhance the overall healthcare experience and improve health outcomes.
Cipla’s vision and mission reflect its unwavering commitment to improving global healthcare. The company’s focus on affordability and patient-centricity drives its efforts to make a meaningful impact on society. With these core values, Cipla continues its legacy of excellence and compassion in the industry.
FAQ’s
What is the share price of Cipla Ltd today?
Cipla Ltd share price as on 18 Apr 2025 is ₹
1515.2
What is the Market Cap of Cipla Ltd?
The market cap of Cipla Ltd stock is ₹1,22,370.15 Cr.
What is the PE Ratio of Cipla Ltd?
The Price to Earnings (P/E) Ratio of Cipla Ltd is 29.60
What is the PB Ratio of Cipla Ltd?
The Price to Book (P/B) Ratio of Cipla Ltd is 4.31
What is the 52 week high of Cipla Ltd Share Price?
The 52 week high of Cipla Ltd share price stands at ₹1,702.05
What is the 52 week low of Cipla Ltd Share Price?
The 52 week low of Cipla Ltd share price stands at ₹1,317.25
How can I buy shares of Cipla Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Cipla Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
